Advertisement

Journal of Neuro-Oncology

, Volume 64, Issue 1–2, pp 139–146 | Cite as

Treatment with allogeneic interleukin-2 secreting fibroblasts protects against the development of malignant brain tumors

  • Roberta P. Glick
  • Terry Lichtor
  • Ripul Panchal
  • Anjuli Mahendra
  • Edward P. Cohen
Enhancing The Response: Immunogene Therapy And Dendritic Cell (DC) Vaccines

Summary

We have reported that mice with an intracerebral (i.c.) malignant glioma or breast cancer treated with i.c. injection of allogeneic fibroblasts genetically engineered to secrete interleukin-2 (IL-2) survived longer than mice in various control groups. The goal of the present study was to determine the effectiveness of utilizing IL-2 secreting allogeneic fibroblasts as a protective treatment to prevent the development of an i.c. glioma or breast carcinoma. Using an intracranial microcannula system that we developed, the animals received weekly injections of the cellular vaccine prior to the introduction of tumor cells via the cannula. The results demonstrate a significant delay (P<0.005) in the development of glioma in the animals pre-treated with either allogeneic non-secreting or IL-2-secreting fibroblasts prior to introduction of tumor cells. In addition, 50% of the animals pre-treated with IL-2 secreting allogeneic fibroblasts injected subsequently with G1261 glioma cells did not develop a tumor, while all of the animals injected with glioma cells alone and 92% of those treated with non-secreting fibroblasts eventually died. The long-term survivors from the pre-treatment group were subsequently re-challenged with tumor and compared to naïve controls. There was evidence that long-term immunity was established in the pre-treated animals, since there was a significant prolongation of survival (P<0.01). In similar experiments using breast cancer cells, 62% of the animals pretreated with non-secreting allogeneic fibroblasts and 75% of the animals pre-treated with allogeneic IL-2 secreting fibroblasts subsequently injected with SB-5b breast carcinoma cells did not develop tumors and had a significant prolongation of survival. These data suggest that i.c. injection of allogeneic IL-2 secreting fibroblasts are effective as a protective treatment in the prevention of the development of a brain tumor when the fibroblasts are introduced into the same site where the tumor is subsequently injected.

Key words

cytokine gene therapy Interleukin-2 tumor vaccine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Valmori D, Levy F, Miconnet I, Zajac P, Spagnoli GC, Rimoldi D, Lienard D, Cerundolo V, Cerottini JC, Romero P: Induction of potent antitumor CTL responses by recombinant vaccinia encoding a melan-A peptide analogue. J Immunol 164: 1125–1131, 2000PubMedGoogle Scholar
  2. 2.
    Gabrilove JL, Jakubowski A: Hematopoietic growth factors: biology and clinical application. J Natl Cancer Inst 10: 73–77, 1990Google Scholar
  3. 3.
    Kelso A: Cytokines: structure function and synthesis. Curr Opin Immunol 2(2): 215–225, 1989PubMedCrossRefGoogle Scholar
  4. 4.
    Borden EC, Sondel PM: Lymphokines and cytokines as cancer treatment. Immunotherapy realized. Cancer 65(3 suppl): 800–814, 1990PubMedCrossRefGoogle Scholar
  5. 5.
    Rosenberg SA, Lotze MT, Mule JJ: New approaches to the immunotherapy of cancer. Ann Intern Med 108: 853–864, 1988PubMedGoogle Scholar
  6. 6.
    Lotze MT, Chang AE, Seipp CA et al.: High-dose recombinant interleukin-2 in the treatment of patients with disseminated cancer: responses, treatment-related morbidity and histologic findings. JAMA 256: 3117–3124, 1986PubMedCrossRefGoogle Scholar
  7. 7.
    Pizza G, Viza D, DeVince C, Vichi-Pascuuchi JM, Busutti L, Bergami T: Intralymphatic administration of interleukin-2 (IL-2) in cancer patients: a pilot study. Cytokine Res 7: 45–48, 1988Google Scholar
  8. 8.
    Sama G, Collins J, Figlin R, Robertson P, Altrock B, Abels R: A pilot study of intralymphatic interleukin-2. II Clinical and biological effects. J Biol Response Modif 9: 81–86, 1990Google Scholar
  9. 9.
    Gandolfi L, Solmi L, Pizza GC, Bertoni F, Muratori R, DeVinci C, Bacchini P, Morelli MC, Corrado G: Intratumoral echo-guided injection of interleukin-2 and cytokine-activated killer cells in hepatocellular carcinoma. Hepato-Gastroenterology 36: 352–356, 1989PubMedGoogle Scholar
  10. 10.
    Bubenik J, Viotenok NN, Kieler J, Prassolov VS, Chumakov PM, Bubenikova D, Simova F, Jandlova T: Local administration of cells containing an inserted IL-2 gene and producing IL-2 inhibits growth of human tumors in nu/nu mice. Immunol Lett 19: 279–282, 1988PubMedCrossRefGoogle Scholar
  11. 11.
    Kim TS, Cohen EP: Interleukin-2-secreting mouse fibroblasts transfected with genomic DNA from murine melanoma cells prolong the survival of mice with melanoma. Cancer Res 54(10): 2531–2535, 1994PubMedGoogle Scholar
  12. 12.
    Kim TS, Russell SJ, Collins MK, Cohen EP: Immunity to B 16 melanoma in mice immunized with IL-2-secreting allogeneic mouse fibroblasts expressing melanoma-associated antigens. Int J Cancer 51(2): 283–289, 1992PubMedCrossRefGoogle Scholar
  13. 13.
    Tahara H, Zeh HJ 3rd, Storkus WJ et al.: Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanomain vivo. Cancer Res 54(1): 182–189, 1994PubMedGoogle Scholar
  14. 14.
    Fakhrai H, Shawler DL, Gjerset R et al.: Cytokine gene therapy with interleukin-2 transduced fibroblasts: effects of IL-2 dose on anti-tumor immunity. Hum Gene Ther 6: 591–601, 1995PubMedGoogle Scholar
  15. 15.
    Sobol RE, Fakhrai H, Shawler DL et al.: Interleukin-2 gene therapy in a patient with glioblastoma. Gene Ther 2: 164–167, 1995PubMedGoogle Scholar
  16. 16.
    Lichtor T, Glick PP, Kim TS, Hand R, Cohen EP: Prolonged survival of mice with glioma injected intracerebrally with double cvtokine-secreting cells. J Neurosurg 83: 1038–1044, 1995PubMedGoogle Scholar
  17. 17.
    Deshmukh P, Glick RP, Lichtor T, Moser R, Cohen EP: Immunogene Therapy with Interleukin-2-Secreting Fibroblasts for Intracerebrally Metastasizing Breast Cancer in Mice. J Neurosurg 94: 287–292, 2001PubMedCrossRefGoogle Scholar
  18. 18.
    Glick RP, Lichtor T, de Zoeten E, Deshmukh P, Cohen EP: Prolongation of survival of mice with glioma treated with semiallogeneic fibroblasts secreting interleukin-2. Neurosurgery 45: 867–874, 1999PubMedCrossRefGoogle Scholar
  19. 19.
    Yu JS, Burwick JA, Dranoff G, Breakefield XO: Gene therapy for metastatic brain tumors by vaccination with granulocyte-macrophage colony-stimulating factor-transduced tumor cells. Hum Gene Ther 8: 1065–1072, 1997PubMedCrossRefGoogle Scholar
  20. 20.
    Sampson J, Archer G, Ashley D, Fuchs H, Hale L, Dranoff G, Bigner D: Subcutaneous vaccination with irradiated cytokine producing tumor cells stimulates CD8+ cell mediated immunity against tumors located in the ‘immunologically privileged’ CNS. Proc Natl Acad Sci USA 93: 10399–10404, 1996PubMedCrossRefGoogle Scholar
  21. 21.
    Giezeman-Smits K, Okada H, Brissette-Storkus C, Villa L, Attanucci J, Lotze M, Pollack I, Bozik M, Chambers W: Cytokine Gene Therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4 transfected 9L gliosarcoma is essential for protective immunity. Cancer Res 60: 2449–2457, 2000PubMedGoogle Scholar
  22. 22.
    Herrlinger U, Kramm C, Johnston K, Louis D, Finkelstein D, Reznikoff G, Dranoff Gbreakefield X, Yu J: Vaccination for experimental gliomas using GM-CSF transduced glioma. Cancer Gene Ther 4: 345–352, 1997PubMedGoogle Scholar
  23. 23.
    Natsume A, Mizuno M, Ryuke Y, Yoshida J: Antitumor effect and cellular immunity activation by murine interferon beta gene transfer against intracerebral glioma in mouse. Gene Ther 6: 1626–1633, 1999PubMedCrossRefGoogle Scholar
  24. 24.
    Yamada G, Kitamura Y, Sonoda H, Harda H, Taki S, Mulligan RC, Osawa H, Diamantstein T, Yokoyama S, Taniguchi T: Retroviral expression of the human IL-2 gene in a murine T cell line results in a cell growth autonomy and tumorigenicity. EMBO J 6: 2705–2709, 1987PubMedGoogle Scholar
  25. 25.
    Cobere-Garapin F, Horodniceanu F, Kourilsky P, Garapin A: A new dominant hybrid selective marker for eucaryotic cells. J Mol Biol 150: 1–14, 1981CrossRefGoogle Scholar
  26. 26.
    Markowitz D, Goff S, Bank A: Construction and use of a safe and efficient amphotropic packaging cell line. Virology 167: 400–406, 1988PubMedGoogle Scholar
  27. 27.
    Griffitt W, Glick RP, Lichtor T, Haughton DE, Cohen EP: Development of a new mouse brain tumor model using implantatable micro-cannulas. J Neuro-Oncol 41: 17–120, 1999CrossRefGoogle Scholar
  28. 28.
    Lichtor T, Glick RP, Tarlock K, Moffett S, Mouw E, Cohen EP: Application of interleukin-2 secreting syngeneic/allogeneic fibroblasts in the treatment of primary and metastatic brain tumors. Cancer Gene Ther 9: 464–469, 2002PubMedCrossRefGoogle Scholar
  29. 29.
    Ashley DM, Faiola B, Nair S, Hale LP, Bigner DD, Gilboa E: Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med 186: 1177–1182, 1997PubMedCrossRefGoogle Scholar
  30. 30.
    Heimberger AB, Crotty LE, Archer GE, McLendon RE, Friedman A, Dranoff G, Bigner DD, Sampson JH: Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma. J Neuroimmunol 103: 16–25, 2000PubMedCrossRefGoogle Scholar
  31. 31.
    Insug O, Ku G, Ertl HC, Blaszczyk-Thurin M: A dendritic cell vaccine induces protective immunity to intracranial growth of glioma. Anticancer Res 22: 613–621, 2002PubMedGoogle Scholar
  32. 32.
    Hui KM, Sim TF, Foo TT, Oei A-A: Tumor rejection mediated by transfection with allogeneic class I histocompatibility gene. J Immunol 143: 3835–3843, 1989PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 2003

Authors and Affiliations

  • Roberta P. Glick
    • 1
    • 2
    • 3
  • Terry Lichtor
    • 1
    • 2
  • Ripul Panchal
    • 1
  • Anjuli Mahendra
    • 1
  • Edward P. Cohen
    • 4
  1. 1.Department of NeurosurgeryCook County HospitalChicagoUSA
  2. 2.Department of NeurosurgeryRush Medical CollegeUSA
  3. 3.Department of Anatomy and Cell BiologyUniversity of Illinois at ChicagoChicagoUSA
  4. 4.Department of Microbiology and ImmunologyUniversity of Illinois at ChicagoChicagoUSA

Personalised recommendations